Targeting of Drugs to Solid Tumors Using Anti-Her2 Immunoliposomes

References

• Papahadjopoulos D. 30-Year progress for liposomes: from serendipity to molecular design. J Liposome Res 1995; 5: ix–xiv
   Google Scholar
• Lasic D. D., Papahadjopoulos D. Liposomes revisited. Science 1995; 267: 1275–1276
   PubMed Web of Science ®Google Scholar
• Leserman L., Machy P. Ligand targeting of liposomes. Liposomes: From Biophysics to Therapeutics, M. J. Ostro. Marcel Dekker, New York 1987; 157–194
   Google Scholar
• Ranade V. V. Drug delivery systems: Site-specific drug delivery using liposomes as carriers. J Clin Pharmacol 1989; 29: 685–694
   PubMed Web of Science ®Google Scholar
• Straubinger R. M., Lopez N. G., Debs R. J., Hong K., Papahadjopoulos D. Liposome-based therapy of human ovarian cancer: parameters determining potency of negatively charged and antibody-targeted liposomes. Cancer Res 1988; 48: 5237–5245
   PubMed Web of Science ®Google Scholar
• Allen T. M., Chonn A. Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett 1987; 223: 42–46
   PubMed Web of Science ®Google Scholar
• Gabizon A., Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA 1988; 85: 6949–6953
   PubMed Web of Science ®Google Scholar
• Blume G., Cevc G. Liposomes for the sustained drug release in vivo. Biochim Biophys Acta 1990; 1029: 91–97
   PubMed Web of Science ®Google Scholar
• Klibanov A. L., Maruyama K., Torchilin V. P., Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 1990; 268: 235–237
   PubMed Web of Science ®Google Scholar
• Papahadjopoulos D., Allen T., Gabizon A., Mayhew E., Matthay K., Huang S. K., Lee K.-D., Woodle M. C., Lasic D. D., Redemann C., Martin F. J. Sterically stabilized liposomes: Improvements in pharmacokinetics and anti-tumor therapeutic efficacy. Proc Natl Acad Sci USA 1991; 88: 11460–11464
   PubMed Web of Science ®Google Scholar
• Torchilin V. P., Klibanov A. L., Huang L., O'Donnell S., Nossiff N. D., Khaw B. A. Targeted accumulation of polyethylene glycol-coated immunoliposomes in infarcted rabbit myocardium. FASEB J 1992; 6: 2716–2719
   PubMed Web of Science ®Google Scholar
• Klibanov A. L., Maruyama K., Beckerleg A. M., Torchilin V. P., Huang L. Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation lifetime of liposomes depends on the liposome size and is unfavorable for immunoli-posome binding to target. Biochim Biophys Acta 1991; 1062: 142–148
   PubMed Web of Science ®Google Scholar
• Torchilin V. P., Papisov M. I., Bogdanov A. A., Trubetskoy V. S., Omelyanenko V. G. Molecular mechanism of liposome and immunoliposome steric protection with poly(ethylene glycol). Stealth Liposomes, D. Lasic, F. Martin. CRC Press, Boca Raton, FL 1995; 51–62
   Google Scholar
• Allen T. M., Brandeis E., Hansen C. B., Kao G. Y., Zalipsky S. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim Biophys Acta 1995; 1237: 99–108
   PubMed Web of Science ®Google Scholar
• Hansen C. B., Kao G. Y., Moase E. H., Zalipsky S., Allen T. M. Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim Biophys Acta 1995; 1239: 133–144
   PubMed Web of Science ®Google Scholar
• Zalipsky S., Hansen C. B., Lopes de Menezes D.E, Allen T. M. Long-circulating, polyethylene glycol-grafted immunoliposomes. J Controlled Release 1996; 39: 153–161
   Web of Science ®Google Scholar
• Kirpotin D., Park J. W., Hong K., Zalipsky S., Li W.-L., Carter P., Benz C. C., Papahadjopoulos D. Sterically stabilized anti-HER2 immunoliposomes: desin and targeting to human breast cancer cells in vitro. Biochemistry 1997; 36: 66–75
   PubMed Web of Science ®Google Scholar
• Park J. W., Hong K., Carter P., Asgari H., Guo L. Y., Wirth C., Shalaby R., Kotts C., Keller G. A., Wood W. I., Papahadjopoulos D, Benz C. C. Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc Natl Acad Sci USA 1995; 92: 1327–1331
   PubMed Web of Science ®Google Scholar
• Park J. W., Hong K., Kirpotin D. B., Papahadjopoulos D., Benz C. C. Immunoliposomes for cancer treatment. Adv Pharmacol 1997; 40: 399–436
   PubMedGoogle Scholar
• Park J. W., Hong K., Kirpotin D. B., Meyer O., Papahadjopoulos D., Benz C. C. Anti-HER2 immunoliposomes for targeted therapy of human tumors. Cancer Lett 1997; 118: 153–160
   PubMed Web of Science ®Google Scholar
• Park J. W., Colbern G., Hong K., Kirpotin D., Shao Y., Baselga J., Moore D., Papahadjopoulos D., Benz C. C. Targeted intracellular drug delivery via anti-HER2 immunoliposomes yields superior antitumor efficacy. Proc ASCO 1997; 16: 430a
   Google Scholar
• Meyer O., Kirpotin D., Hong K., Sternberg B., Park J. W., Woodle M. C., Papahadjopoulos D. Poly(ethylene glycol)-coated cationic liposomes as carriers for cellular delivery of antisense oligonucleotides. J Biol Chem 1998; 283: 15261–15267
   Google Scholar
• Hynes N. E., Stern D. F. The biology of erbB-2/neu/HER2 and its role in cancer. Biochim Biophys Acta 1994; 1198: 165–184
   PubMed Web of Science ®Google Scholar
• Carraway K. L., Cantley L. C. A neu acquaintance for ErbB3 and ErbB4: a role for receptor heterodimerization in growth signaling. Cell 1994; 78: 5–8
   PubMed Web of Science ®Google Scholar
• Slamon D. J., Clark G. M., Wong S. G., Levin W. J., Ullrich A., McGuire W. L. Human breast cancer: correlation of relapse and survival with amplification of HER2/neu oncogene. Science 1987; 235: 177–182
   PubMed Web of Science ®Google Scholar
• Slamon D. J., Godolphin W., Jones L. A., Holt J. A., Wong S. G., Keith D. E., Levin W. J., Stuart S. G., Udove J., Ullrich A., Press M. Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707–712
   PubMed Web of Science ®Google Scholar
• Berchuck A., Kamel A., Whitaker R., Kerns B., Olt G., Kinney R., Soper J. T., Dodge R., Clarke-Pearson D. L., Marks P., McKenzie S., Yin S., Bast R. C. Overexpression of HER2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990; 50: 4087–4091
   PubMed Web of Science ®Google Scholar
• Berchuck A., Rodriguez G., Kinney R. B., Soper J. T., Dodge R. K., Clarke-Pearson D. L., Bast R. C. Overexpression of HER2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstetrics Gynecol 1991; 164: 15–21
   PubMed Web of Science ®Google Scholar
• Kern J. A., Schwartz D. A., Nordberg J. E., Weiner D. B., Greene M. I., Torney L., Robinson R. A. p185neu expression in human lung adenocarcinomas predict shortened survival. Cancer Res 1990; 50: 5184–5191
   PubMed Web of Science ®Google Scholar
• Yokota J., Yamamoto T., Miyajima N., Toyoshima K., Nomura N., Sakamoto H., Yoshida T., Terada M., Sugimura T. Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of v-erbA homologue. Oncogene 1988; 2: 283–287
   PubMed Web of Science ®Google Scholar
• Park J. B., Rhim J. S., Park S. C., Kimm S. W., Kraus M. H. Amplification, overexpression and rearrangement of the erbB-2 proto-oncogene in primary human stomach carcinomas. Cancer Res 1989; 49: 6605–6609
   PubMed Web of Science ®Google Scholar
• Lei A., Appert H. E., Nakata B., Domenico D. R., Kim K., Howard J. M. Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened survival. In. J Pancreatology 1995; 17: 15–21
   PubMedGoogle Scholar
• Zhau H. E., Zhang X., Von Eschenbach A. C., Scorsone K., Babaian R. J., Ro J. Y., Hung M. C. Amplification and expression of the c-erbB-2/neu proto-oncogene in human bladder cancer. Molec Carcinogenesis 1990; 3: 254–257
   PubMed Web of Science ®Google Scholar
• Gu K., Mes-Masson A.-M., Gauthier J, Saad F. Overexpression of her-2/neu, in human prostate cancer and benign hyperplasia. Cancer Lett 1996; 99: 185–189
   PubMed Web of Science ®Google Scholar
• VandeVijver M. J., Peterse M. L., Mooi W. J., Wisman O., Lomans J., Dalesio O., Nusse R. Neu-protein expression in breast cancer. New Engl J Med 1988; 319: 1239–1245
   PubMed Web of Science ®Google Scholar
• Liu E., Thor A., He M., Barcos M., Ljung B. M., Benz C. C. The HER2 (c-erbB-2) oncogene is frequently amplified in in situ, carcinomas of the breast. Oncogene 1992; 7: 1027–1032
   PubMed Web of Science ®Google Scholar
• Lewis G. D., Figari I., Fendly B. M., Wong W.-L., Carter P., Gorman C., Shepard H. M. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 1993; 37: 255–263
   PubMed Web of Science ®Google Scholar
• Press M. F., Cordon-Cardo C., Slamon D. J. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 1990; 5: 953–962
   PubMed Web of Science ®Google Scholar
• Niehans G. A., Singleton T. P., Dykoski D., Kiang D. T. Stability of HER-2/neu expression over time and at multiple metastatic sites. J Natl Cancer Inst 1993; 85: 1230–1235
   PubMed Web of Science ®Google Scholar
• Tagliabue E., Centis P., Campiglio M., Mastroiannini A., Martignone S, Pellegrini R., Casalani P., Lanzi C., Menard S., Colnaghi M. I. Selecion of monoclonal antibodies which induce internalization and phosphorylation of p185HER2 and growth inhibition of cells with HER2/neu gene amplification. Int J Cancer 1991; 47: 933–937
   PubMed Web of Science ®Google Scholar
• Sarup J. C., Johnson R. M., King K. L., Fendly B. M., Lipari M. T., Napier M. A., Ullrich A., Shepard H. M. Characterization of an anti-p185HER2 monoclonal antibody that stimulated receptor function and inhibits tumor cell growth. Growth Regulation 1991; 37: 72–82
   Google Scholar
• Hurwitz E., Stancovski I., Sela M., Yarden Y. Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. Proc Natl Acad Sci USA 1995; 92: 3553–3557
   Web of Science ®Google Scholar
• Fendly B. M., Winget M., Hudziak R. M., Lipari M. T., Napier M. A., Ullrich A. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 1990; 50: 1550–1558
   PubMed Web of Science ®Google Scholar
• Schier R., Marks J. D., Wolf E. J., Apell G., Wong C., McCartney J. E., Bookman M. A., Huston J. A., Houston L. L., Weiner L. M., Adams G. P. In vitro, and in vivo, characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library. Immunotechnology 1995; 1: 73–81
   PubMedGoogle Scholar
• Schier R., McCal A., Adams G. P., Marshall K. W., Merritt H., Yim M., Craford R. S., Weiner L. M., Marks C., Marks J. D. Isolation of picomolar affinity anti-c-erbB-2 single chain Fv by molecular evolution of the complementary determining regions in the center of the antibody binding site. J Mol Biol 1996; 263: 551–567
   PubMed Web of Science ®Google Scholar
• Park J. W., Stagg R., Lewis G. D., Carter P., Maneval D., Slamon D. J., Jaffe H., Shepard H. M. Anti-p185HER2 monoclonal antibodies: biological properties and potential for immunotherapy. Genes, Oncogenes, and Hormones: Advances in Cellular and Molecular Biology of Breast Cancer, R. B. Dickson, M. E. Lippman. Kluwer, Boston, MA 1992; 193–211
   Google Scholar
• Carter P., Presta L., Gorman C. M., Ridgway J. B.B., Henner D., Wong W. L.T., Rowland A. M., Kotts C., Carver M. E., Shepard H. M. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992; 89: 4285–4289
   PubMed Web of Science ®Google Scholar
• Baselga J., Tripathy D., Mendelsohn J., Baughman S., Benz C. C., Dantis L., Sklarin N. T., Seidman A. D., Hudis C. A., Moore J., Rosen P. P., Twaddell T., Henderson I. C., Norton L. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neuoverexpressing metastatic breast cancer. J Clin Oncol. 1996; 14: 737–744
   PubMed Web of Science ®Google Scholar
• Papahadjopoulos D., Jacobson K., Nir S., Isac T. Phase transitions in phospholipid vesicles, fluorescence polarization and permeability measurements concerning the effect of temperature and cholesterol. Biochim Biophys Acta 1973; 311: 330–348
   PubMed Web of Science ®Google Scholar
• Olson F., Hunt C. A., Szoka F. C., Vail W. J., Papahadjopoulos D. Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes. Biochim Biophys Acta 1979; 557: 9–23
   PubMed Web of Science ®Google Scholar
• Martin F., Papahadjopoulos D. Irreversible coupling of immunoglobulin fragments to preformed vesicles. An improved method for liposome targeting. J Biol Chem 1982; 257: 286–288
   PubMed Web of Science ®Google Scholar
• Shahinian S., Silvius J. R. A novel strategy affords high-yield coupling of antibody Fab′ fragments to liposomes. Biochim Biophys Acta 1995; 1239: 157–167
   PubMed Web of Science ®Google Scholar
• Loughrey H. C., Choi L. S., Cullis P. R., Bally M. B. Optimized procedures for the coupling of proteins to liposomes. J Immunol Methods 1990; 132: 25–35
   PubMed Web of Science ®Google Scholar
• Bredehorst R., Ligler F. S., Kusterbeck A. W., Chang E. L., Gaber B. P., Vogel C.-W. Effect of covalent attachment of immunoglobulin fragments on liposomal integrity. Biochemistry 1986; 25: 5693–5698
   PubMed Web of Science ®Google Scholar
• Hristova K., Needham D. Physical properties of polymer-grafted bilayers. Stealth Liposomes, D. Lasic, F. Martin. CRC Press, Boca Raton, FL 1995; 35–49
   Google Scholar
• Mori A., Klibanov A. L., Torchilin V. P., Huang L. Influence of the steric barrier activity of amphipathic poly(ethylene glycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo. FEBS Lett 1991; 284: 263–266
   PubMed Web of Science ®Google Scholar
• Huang S. K., Mayhew E., Gilani S., Lasic D. D., Martin F. J., Papahadjopoulos D. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res 1992; 52: 6774–6781
   PubMed Web of Science ®Google Scholar
• Working P. W., Newman M., Huang S. K., Vaage J., Mayhew E., Lasic D. D. Pharmacokinetics, biodistribution and therapeutic efficacy of doxorubicin encapsulated in Stealth liposomes. J Liposome Res 1994; 4: 667–675
   Google Scholar
• Bogner J. R., Goebel F.-D. Efficacy of Dox-SL (Stealth liposomal doxorubicin) in the treatment of advanced AIDS-related Kaposi's sarcoma. Stealth Liposomes, D. Lasic, F. Martin. CRC Press, Boca Raton, FL 1995; 267–278
   Google Scholar
• Haran G., Cohen R., Bar L. K., Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1993; 1149: 180–184
   PubMed Web of Science ®Google Scholar
• Daleke D. L., Hong K., Papahadjopoulos D. Endocytosis of liposomes by macrophages: binding, acidification, and leakage of liposomes monitored by a new fluorescence assay. Biochim Biophys Acta 1990; 1024: 352–366
   PubMed Web of Science ®Google Scholar
• Maruyama K., Takizawa T., Yuda T., Kennel S. J., Huang L., Iwatsuru M. Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies. Biochim Biophys Acta 1995; 1234: 74–80
   PubMed Web of Science ®Google Scholar
• Nezlin R. C. Structure and biosynthesis of antibodies. Consultants Bureau, New York, NY 1977; 174
   Google Scholar
• Kenworthy A. K., Simon S. A., McIntosh T. J. Structure and phase behavior of lipid suspensions containing phospholipids with covalently attached poly(ethylene glycol). Biophys J 1995; 68: 1903–1920
   PubMed Web of Science ®Google Scholar
• Lee K.-D., Nir S., Papahadjopoulos D. Quantitative analysis of liposome-cell interactions in vitro: rate constants of binding and endocytosis with suspension and adherent J774 cells and human monocytes. Biochemistry 1993; 32: 889–899
   PubMed Web of Science ®Google Scholar
• Goren D., Horowitz A. T., Zalipsky S., Woodle M. C., Yarden Y., Gabizon A. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro, and in vivo, studies. Br J Cancer 1996; 74: 1749–1756
   PubMed Web of Science ®Google Scholar
• Suzuki S., Uno S., Fukuda Y., Aoki Y., Masuko T., Hashimoto Y. Cytotoxicity of anti-c-erbB-2 immunoliposomes containing doxorubicin on human cancer cells. Br J Cancer 1995; 72: 663–668
   PubMed Web of Science ®Google Scholar
• Gabizon A., Huberty J., Straubinger R., Price D. C., Papahadjopoulos D. An improved method for in vivo, tracing and imaging of liposomes using Gallium-67- deferoxamine complex. J Liposome Res 1988; 1: 123–135
   Google Scholar
• Heitjan D. F. Generalized Norton-Simon models of tumor growth. Statistics in Medicine 1991; 10: 1075–1088
   PubMed Web of Science ®Google Scholar
• Kirpotin D B, Park J W, Hong K, Shao Y, Shalaby R, Colbern G, Benz C C, Papahadjopoulos D. Targeting of liposomes to solid tumors: The case of the sterically stabilized anti-HER2 immunoliposomes. Forum on Liposomes targeting in animal models. J Lipo Res 1997; 7(4)391–417
   Google Scholar
• Kirpotin D. B., Park J. W., Hong K, Shao Y, Colbern G, Zheng W, Meyer O, Benz C C, Papahadjopoulos D. Targeting of Sterically Stabilized Liposomes to Cancers Overexpressing HER2/neu Proto-oncogene. Medical Applications of Liposomes, D Lasic, D Papahadjopoulos. Elsevier Publishers, AmsterdamThe Netherlands 1998
   Google Scholar
• Matzku S., Krempel H., Weckenmann H.-P., Schirrmacher V., Sinn H., Stricker H. Tumour targeting with antibody-coupled liposomes: failure to achieve accumulation in xenografts and spontaneous liver metastases. Cancer Immunol Immunother 1990; 31: 285–291
   PubMed Web of Science ®Google Scholar
• Hong K., Friend D. S., Glabe C. G., Papahadjopoulos D. Liposomes containing colloidal gold are a useful probe of liposome-cell interactions. Biochim Biophys Acta 1983; 732: 320–323
   PubMed Web of Science ®Google Scholar
• Huang S. K., Lee K.-D., Hong K., Friend D. S., Papahadjopoulos D. Microscopic localization of sterically stabilized liposomes in colon-carcinoma bearing mice. Cancer Res 1992; 52: 5135–5143
   PubMed Web of Science ®Google Scholar
• Madden T. D., Harrigan P. R., Tai L. C., Bally M. B., Mayer L. D., Redelmeier T. E., Loughrey H. C., Tilcock C. P., Reinish L. W., Cullis P. R. The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. Chem Phys Lipids 1990; 53: 37–46
   PubMed Web of Science ®Google Scholar
• Janknegt R. Liposomal formulations of cytotoxic drugs. Supportive Care Cancer 1996; 4: 298–304
   PubMed Web of Science ®Google Scholar